South & Central America Biopharmaceutical Contract Manufacturing Market Size and Forecast (2021 - 2031), Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product Type (Biologics and Biosimilar), Source (Microbial and Mammalian), Application (Commercial and Clinical), and Therapeutic Area (Oncology, Autoimmune Disorders, Respiratory Disorders, Metabolic Disorders, Neurology, Infectious Diseases, and Others)
The South & Central America Biopharmaceutical Contract Manufacturing Market is poised for significant growth, with projections indicating an increase from US$ 1,766.4 million in 2024 to US$ 4,155.6 million by 2031. This growth represents a compound annual growth rate (CAGR) of 13.1% from 2025 to 2031, driven by several key factors.
The region, which includes Brazil, Argentina, and other countries, is witnessing a surge in clinical trials, which is boosting the demand for contract manufacturing services. Pharmaceutical and biotechnology companies are increasingly seeking cost-effective and high-quality production solutions, making contract manufacturing organizations (CMOs) an attractive option. Brazil and Argentina are emerging as regional hubs for biopharmaceutical manufacturing, supported by robust healthcare infrastructure, a skilled workforce, and favorable regulatory environments.
The efficiency of clinical trials is improving due to the adoption of adaptive trial designs and digital health technologies, which help to reduce timelines and encourage investment in the region. Additionally, various government initiatives aimed at enhancing local pharmaceutical capabilities, regulatory harmonization, and attracting foreign investments have created a conducive business environment. These factors position South & Central America as a competitive market for biopharmaceutical contract manufacturing.
Market Segmentation
The South & Central America Biopharmaceutical Contract Manufacturing Market can be segmented by product type, source, application, and therapeutic area:
A significant opportunity in the market is the rise of personalized medicine, which tailors treatments to the unique genetic profiles and lifestyles of individual patients. The advancements in genomics, biotechnology, and diagnostics are facilitating the adoption of personalized medicine, leading to increased demand for specialized, flexible, and scalable manufacturing solutions. As biopharmaceutical companies develop personalized therapies, they are increasingly collaborating with CMOs that can provide the necessary expertise and capacity for these specialized manufacturing needs.
For instance, in March 2024, Brazil's Fiocruz partnered with the U.S.-based nonprofit Caring Cross to enhance local manufacturing capabilities for CAR-T cell therapies and lentiviral vectors. This collaboration, which includes technology transfer and infrastructure development, is a significant step in improving Brazil's contract manufacturing capabilities for patient-specific treatments, addressing the growing demand for personalized medicine.
The trend towards personalized therapies necessitates efficient and adaptable manufacturing processes, particularly for cell-based therapies and gene-editing technologies like CRISPR. CMOs that can offer specialized services for these advanced treatments are well-positioned to capitalize on the personalized medicine trend, as companies shift towards smaller batch sizes and more customized production.
Country Insights
The market is further segmented by country, with Brazil and Argentina being the primary players. Brazil is expected to maintain the largest market share in 2024. A notable development in Brazil's biopharmaceutical landscape was the agreement between Pfizer Inc. and BioNTech SE with Eurofarma Laborat?rios SA to manufacture the COVID-19 mRNA vaccine, COMIRNATY. This collaboration highlights Brazil's growing role as a strategic manufacturing base for high-value biologics, particularly in response to the urgent need for localized vaccine production in Latin America.
Brazil's capabilities in advanced technologies, such as mRNA platforms, reinforce confidence in its manufacturing standards and regulatory environment. The opportunity lies in leveraging this momentum to expand contract development and manufacturing organization (CDMO) services beyond vaccines to include other complex biologics, such as monoclonal antibodies and biosimilars. With established infrastructure and a skilled workforce, Brazil is well-positioned to become the leading biopharmaceutical manufacturing and distribution hub in the region.
Key Players
Key players in the South & Central America Biopharmaceutical Contract Manufacturing Market include Boehringer Ingelheim International GmbH, Lonza Group AG, AbbVie Inc., Samsung Biologics Co., Ltd, WuXi Biologics Inc., Merck KGaA, Ajinomoto Co., Inc., Cytiva, and AGC Biologics AS. These companies are employing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their market presence and offer innovative products to consumers.
The region, which includes Brazil, Argentina, and other countries, is witnessing a surge in clinical trials, which is boosting the demand for contract manufacturing services. Pharmaceutical and biotechnology companies are increasingly seeking cost-effective and high-quality production solutions, making contract manufacturing organizations (CMOs) an attractive option. Brazil and Argentina are emerging as regional hubs for biopharmaceutical manufacturing, supported by robust healthcare infrastructure, a skilled workforce, and favorable regulatory environments.
The efficiency of clinical trials is improving due to the adoption of adaptive trial designs and digital health technologies, which help to reduce timelines and encourage investment in the region. Additionally, various government initiatives aimed at enhancing local pharmaceutical capabilities, regulatory harmonization, and attracting foreign investments have created a conducive business environment. These factors position South & Central America as a competitive market for biopharmaceutical contract manufacturing.
Market Segmentation
The South & Central America Biopharmaceutical Contract Manufacturing Market can be segmented by product type, source, application, and therapeutic area:
- By Product Type: The market is divided into Biologics and Biosimilars, with Biologics holding the largest market share in 2024.
- By Source: The segmentation includes Microbial and Mammalian sources, where Microbial is expected to dominate the market.
- By Application: The market is categorized into Commercial and Clinical applications, with Commercial applications leading in market share.
- By Therapeutic Area: This includes Oncology, Autoimmune Disorders, Respiratory Disorders, Metabolic Disorders, Neurology, Infectious Diseases, and others, with Oncology being the largest segment in 2024.
A significant opportunity in the market is the rise of personalized medicine, which tailors treatments to the unique genetic profiles and lifestyles of individual patients. The advancements in genomics, biotechnology, and diagnostics are facilitating the adoption of personalized medicine, leading to increased demand for specialized, flexible, and scalable manufacturing solutions. As biopharmaceutical companies develop personalized therapies, they are increasingly collaborating with CMOs that can provide the necessary expertise and capacity for these specialized manufacturing needs.
For instance, in March 2024, Brazil's Fiocruz partnered with the U.S.-based nonprofit Caring Cross to enhance local manufacturing capabilities for CAR-T cell therapies and lentiviral vectors. This collaboration, which includes technology transfer and infrastructure development, is a significant step in improving Brazil's contract manufacturing capabilities for patient-specific treatments, addressing the growing demand for personalized medicine.
The trend towards personalized therapies necessitates efficient and adaptable manufacturing processes, particularly for cell-based therapies and gene-editing technologies like CRISPR. CMOs that can offer specialized services for these advanced treatments are well-positioned to capitalize on the personalized medicine trend, as companies shift towards smaller batch sizes and more customized production.
Country Insights
The market is further segmented by country, with Brazil and Argentina being the primary players. Brazil is expected to maintain the largest market share in 2024. A notable development in Brazil's biopharmaceutical landscape was the agreement between Pfizer Inc. and BioNTech SE with Eurofarma Laborat?rios SA to manufacture the COVID-19 mRNA vaccine, COMIRNATY. This collaboration highlights Brazil's growing role as a strategic manufacturing base for high-value biologics, particularly in response to the urgent need for localized vaccine production in Latin America.
Brazil's capabilities in advanced technologies, such as mRNA platforms, reinforce confidence in its manufacturing standards and regulatory environment. The opportunity lies in leveraging this momentum to expand contract development and manufacturing organization (CDMO) services beyond vaccines to include other complex biologics, such as monoclonal antibodies and biosimilars. With established infrastructure and a skilled workforce, Brazil is well-positioned to become the leading biopharmaceutical manufacturing and distribution hub in the region.
Key Players
Key players in the South & Central America Biopharmaceutical Contract Manufacturing Market include Boehringer Ingelheim International GmbH, Lonza Group AG, AbbVie Inc., Samsung Biologics Co., Ltd, WuXi Biologics Inc., Merck KGaA, Ajinomoto Co., Inc., Cytiva, and AGC Biologics AS. These companies are employing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their market presence and offer innovative products to consumers.
1. INTRODUCTION
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET LANDSCAPE
4.1 PEST Analysis
5. SOUTH & CENTRAL AMERICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET - KEY MARKET DYNAMICS
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:
6. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET - SOUTH & CENTRAL AMERICA MARKET ANALYSIS
6.1 South & Central America Biopharmaceutical Contract Manufacturing Market Revenue (US$ Million), 2024 - 2031
6.2 South & Central America Biopharmaceutical Contract Manufacturing Market Forecast and Analysis
7. SOUTH & CENTRAL AMERICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE ANALYSIS - BY PRODUCT TYPE
7.1 Biologics
7.1.1 Overview
7.1.2 Biologics: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.2 Biosimilar
7.2.1 Overview
7.2.2 Biosimilar: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8. SOUTH & CENTRAL AMERICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE ANALYSIS - BY SOURCE
8.1 Microbial
8.1.1 Overview
8.1.2 Microbial: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.2 Mammalian
8.2.1 Overview
8.2.2 Mammalian: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9. SOUTH & CENTRAL AMERICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE ANALYSIS - BY APPLICATION
9.1 Commercial
9.1.1 Overview
9.1.2 Commercial: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.2 Clinical
9.2.1 Overview
9.2.2 Clinical: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10. SOUTH & CENTRAL AMERICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE ANALYSIS - BY THERAPEUTIC AREA
10.1 Oncology
10.1.1 Overview
10.1.2 Oncology: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.2 Autoimmune Disorders
10.2.1 Overview
10.2.2 Autoimmune Disorders: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.3 Respiratory Disorders
10.3.1 Overview
10.3.2 Respiratory Disorders: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.4 Metabolic Disorders
10.4.1 Overview
10.4.2 Metabolic Disorders: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.5 Neurology
10.5.1 Overview
10.5.2 Neurology: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.6 Infectious Diseases
10.6.1 Overview
10.6.2 Infectious Diseases: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.7 Others
10.7.1 Overview
10.7.2 Others: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11. SOUTH & CENTRAL AMERICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET - COUNTRY ANALYSIS
11.1 South & Central America
11.1.1 South & Central America Biopharmaceutical Contract Manufacturing Market Revenue and Forecast and Analysis - by Country
11.1.1.1 South & Central America Biopharmaceutical Contract Manufacturing Market Revenue and Forecast and Analysis - by Country
11.1.2.2 Brazil: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.1.2.2.1 Brazil: South & Central America Biopharmaceutical Contract Manufacturing Market Share - by Product Type
11.1.2.2.2 Brazil: South & Central America Biopharmaceutical Contract Manufacturing Market Share - by Source
11.1.2.2.3 Brazil: South & Central America Biopharmaceutical Contract Manufacturing Market Share - by Application
11.1.2.2.4 Brazil: South & Central America Biopharmaceutical Contract Manufacturing Market Share - by Therapeutic Area
11.2.3.3 Argentina: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.2.3.3.1 Argentina: South & Central America Biopharmaceutical Contract Manufacturing Market Share - by Product Type
11.2.3.3.2 Argentina: South & Central America Biopharmaceutical Contract Manufacturing Market Share - by Source
11.2.3.3.3 Argentina: South & Central America Biopharmaceutical Contract Manufacturing Market Share - by Application
11.2.3.3.4 Argentina: South & Central America Biopharmaceutical Contract Manufacturing Market Share - by Therapeutic Area
11.3.4.4 Rest of South & Central America: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.3.4.4.1 Rest of South & Central America: South & Central America Biopharmaceutical Contract Manufacturing Market Share - by Product Type
11.3.4.4.2 Rest of South & Central America: South & Central America Biopharmaceutical Contract Manufacturing Market Share - by Source
11.3.4.4.3 Rest of South & Central America: South & Central America Biopharmaceutical Contract Manufacturing Market Share - by Application
11.3.4.4.4 Rest of South & Central America: South & Central America Biopharmaceutical Contract Manufacturing Market Share - by Therapeutic Area
12 COMPETITIVE LANDSCAPE
12.1 Heat Map Analysis by Key Players
12.2 Company Positioning & Concentration
13 INDUSTRY LANDSCAPE
13.1 Overview
13.2 New Product Development
13.3 Merger and Acquisition
13.4 Other Strategic Developments
14 COMPANY PROFILES
14.1 Boehringer Ingelheim International GmbH
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Lonza Group AG
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 AbbVie Inc
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Samsung Biologics Co Ltd
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 WuXi Biologics Inc
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Merck KGaA
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 Ajinomoto Co Inc
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Cytiva
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 AGC Biologics AS
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
15. APPENDIX
15.1 About The Insight Partners
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET LANDSCAPE
4.1 PEST Analysis
5. SOUTH & CENTRAL AMERICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET - KEY MARKET DYNAMICS
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:
6. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET - SOUTH & CENTRAL AMERICA MARKET ANALYSIS
6.1 South & Central America Biopharmaceutical Contract Manufacturing Market Revenue (US$ Million), 2024 - 2031
6.2 South & Central America Biopharmaceutical Contract Manufacturing Market Forecast and Analysis
7. SOUTH & CENTRAL AMERICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE ANALYSIS - BY PRODUCT TYPE
7.1 Biologics
7.1.1 Overview
7.1.2 Biologics: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.2 Biosimilar
7.2.1 Overview
7.2.2 Biosimilar: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8. SOUTH & CENTRAL AMERICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE ANALYSIS - BY SOURCE
8.1 Microbial
8.1.1 Overview
8.1.2 Microbial: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.2 Mammalian
8.2.1 Overview
8.2.2 Mammalian: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9. SOUTH & CENTRAL AMERICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE ANALYSIS - BY APPLICATION
9.1 Commercial
9.1.1 Overview
9.1.2 Commercial: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.2 Clinical
9.2.1 Overview
9.2.2 Clinical: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10. SOUTH & CENTRAL AMERICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE ANALYSIS - BY THERAPEUTIC AREA
10.1 Oncology
10.1.1 Overview
10.1.2 Oncology: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.2 Autoimmune Disorders
10.2.1 Overview
10.2.2 Autoimmune Disorders: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.3 Respiratory Disorders
10.3.1 Overview
10.3.2 Respiratory Disorders: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.4 Metabolic Disorders
10.4.1 Overview
10.4.2 Metabolic Disorders: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.5 Neurology
10.5.1 Overview
10.5.2 Neurology: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.6 Infectious Diseases
10.6.1 Overview
10.6.2 Infectious Diseases: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.7 Others
10.7.1 Overview
10.7.2 Others: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11. SOUTH & CENTRAL AMERICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET - COUNTRY ANALYSIS
11.1 South & Central America
11.1.1 South & Central America Biopharmaceutical Contract Manufacturing Market Revenue and Forecast and Analysis - by Country
11.1.1.1 South & Central America Biopharmaceutical Contract Manufacturing Market Revenue and Forecast and Analysis - by Country
11.1.2.2 Brazil: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.1.2.2.1 Brazil: South & Central America Biopharmaceutical Contract Manufacturing Market Share - by Product Type
11.1.2.2.2 Brazil: South & Central America Biopharmaceutical Contract Manufacturing Market Share - by Source
11.1.2.2.3 Brazil: South & Central America Biopharmaceutical Contract Manufacturing Market Share - by Application
11.1.2.2.4 Brazil: South & Central America Biopharmaceutical Contract Manufacturing Market Share - by Therapeutic Area
11.2.3.3 Argentina: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.2.3.3.1 Argentina: South & Central America Biopharmaceutical Contract Manufacturing Market Share - by Product Type
11.2.3.3.2 Argentina: South & Central America Biopharmaceutical Contract Manufacturing Market Share - by Source
11.2.3.3.3 Argentina: South & Central America Biopharmaceutical Contract Manufacturing Market Share - by Application
11.2.3.3.4 Argentina: South & Central America Biopharmaceutical Contract Manufacturing Market Share - by Therapeutic Area
11.3.4.4 Rest of South & Central America: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.3.4.4.1 Rest of South & Central America: South & Central America Biopharmaceutical Contract Manufacturing Market Share - by Product Type
11.3.4.4.2 Rest of South & Central America: South & Central America Biopharmaceutical Contract Manufacturing Market Share - by Source
11.3.4.4.3 Rest of South & Central America: South & Central America Biopharmaceutical Contract Manufacturing Market Share - by Application
11.3.4.4.4 Rest of South & Central America: South & Central America Biopharmaceutical Contract Manufacturing Market Share - by Therapeutic Area
12 COMPETITIVE LANDSCAPE
12.1 Heat Map Analysis by Key Players
12.2 Company Positioning & Concentration
13 INDUSTRY LANDSCAPE
13.1 Overview
13.2 New Product Development
13.3 Merger and Acquisition
13.4 Other Strategic Developments
14 COMPANY PROFILES
14.1 Boehringer Ingelheim International GmbH
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Lonza Group AG
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 AbbVie Inc
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Samsung Biologics Co Ltd
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 WuXi Biologics Inc
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Merck KGaA
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 Ajinomoto Co Inc
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Cytiva
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 AGC Biologics AS
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
15. APPENDIX
15.1 About The Insight Partners
LIST OF TABLES
Table 1. South & Central America Biopharmaceutical Contract Manufacturing Market Segmentation
Table 3. South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Table 4. South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 5. South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 6. South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 7. South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 8. South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Country
Table 9. Brazil: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 10. Brazil: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 11. Brazil: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 12. Brazil: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 13. Argentina: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 14. Argentina: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 15. Argentina: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 16. Argentina: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 17. Rest of South & Central America: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 18. Rest of South & Central America: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 19. Rest of South & Central America: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 20. Rest of South & Central America: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 21. Heat Map Analysis by Key Players
Table 1. South & Central America Biopharmaceutical Contract Manufacturing Market Segmentation
Table 3. South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Table 4. South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 5. South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 6. South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 7. South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 8. South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Country
Table 9. Brazil: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 10. Brazil: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 11. Brazil: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 12. Brazil: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 13. Argentina: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 14. Argentina: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 15. Argentina: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 16. Argentina: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 17. Rest of South & Central America: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 18. Rest of South & Central America: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 19. Rest of South & Central America: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 20. Rest of South & Central America: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 21. Heat Map Analysis by Key Players
LIST OF FIGURES
Figure 1. South & Central America Biopharmaceutical Contract Manufacturing Market Segmentation - Country
Figure 2. PEST Analysis
Figure 4. South & Central America Biopharmaceutical Contract Manufacturing Market - Key Market Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. South & Central America Biopharmaceutical Contract Manufacturing Market Revenue (US$ Million), 2024 - 2031
Figure 7. South & Central America Biopharmaceutical Contract Manufacturing Market Share (%) - by Product Type, 2024 and 2031
Figure 8. Biologics: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 9. Biosimilar: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 10. South & Central America Biopharmaceutical Contract Manufacturing Market Share (%) - by Source, 2024 and 2031
Figure 11. Microbial: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 12. Mammalian: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 13. South & Central America Biopharmaceutical Contract Manufacturing Market Share (%) - by Application, 2024 and 2031
Figure 14. Commercial: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 15. Clinical: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 16. South & Central America Biopharmaceutical Contract Manufacturing Market Share (%) - by Therapeutic Area, 2024 and 2031
Figure 17. Oncology: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 18. Autoimmune Disorders: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 19. Respiratory Disorders: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 20. Metabolic Disorders: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 21. Neurology: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 22. Infectious Diseases: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 23. Others: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 24. South & Central America Biopharmaceutical Contract Manufacturing Market Breakdown by Key Countries, 2024 and 2031 (%)
Figure 25. Brazil: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 26. Argentina: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 27. Rest of South & Central America: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 28. Company Positioning & Concentration
Figure 1. South & Central America Biopharmaceutical Contract Manufacturing Market Segmentation - Country
Figure 2. PEST Analysis
Figure 4. South & Central America Biopharmaceutical Contract Manufacturing Market - Key Market Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. South & Central America Biopharmaceutical Contract Manufacturing Market Revenue (US$ Million), 2024 - 2031
Figure 7. South & Central America Biopharmaceutical Contract Manufacturing Market Share (%) - by Product Type, 2024 and 2031
Figure 8. Biologics: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 9. Biosimilar: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 10. South & Central America Biopharmaceutical Contract Manufacturing Market Share (%) - by Source, 2024 and 2031
Figure 11. Microbial: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 12. Mammalian: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 13. South & Central America Biopharmaceutical Contract Manufacturing Market Share (%) - by Application, 2024 and 2031
Figure 14. Commercial: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 15. Clinical: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 16. South & Central America Biopharmaceutical Contract Manufacturing Market Share (%) - by Therapeutic Area, 2024 and 2031
Figure 17. Oncology: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 18. Autoimmune Disorders: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 19. Respiratory Disorders: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 20. Metabolic Disorders: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 21. Neurology: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 22. Infectious Diseases: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 23. Others: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 24. South & Central America Biopharmaceutical Contract Manufacturing Market Breakdown by Key Countries, 2024 and 2031 (%)
Figure 25. Brazil: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 26. Argentina: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 27. Rest of South & Central America: South & Central America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 28. Company Positioning & Concentration
